Need professional-grade analysis? Visit stockanalysis.com
$11.01B
25.57
1,784
N/A
Aurisco Pharmaceutical Co Ltd (605116) trades on SHG in CNY. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at CNY26.27, down 4.68% from the previous close.
Over the past year, 605116 has traded between a low of CNY20.41 and a high of CNY34.43. The stock has gained 25.1% over this period. It is currently 23.7% below its 52-week high.
Aurisco Pharmaceutical Co Ltd has a market capitalization of $11.01B, with a price-to-earnings ratio of 25.57.
Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides dexamethasone is used to treat skin diseases; fluticasone propionate preparations are used to treat asthma and allergic rhinitis; fluticasone furoate preparations are used to treat asthma, allergic rhinitis, and chronic obstructive pulmonary disease; eplerenone preparations are used for the treatment of hypertension and heart failure; bepedalic acid preparations are used for the treatment of hypercholesterolemia or atherosclerotic cardiovascular diseases; tenofovir used for the treatment of HIV-1 infection and chronic hepatitis B; pregabalin preparations are used to treat neuropathic pain, fibromyalgia, epilepsy, etc.; brivaracetam preparations are used to treat epilepsy; abiraterone acetate and enzalutamide preparation preparations for the treatment of prostate cancer; and dydrogesterone preparations are used to treat dysmenorrhea, endometriosis, irregular menstrual cycle, etc. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.
Side-by-side comparison against top Healthcare peers.